

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/079818 A3

(51) International Patent Classification⁷: G01N 21/55, 21/35, A61B 5/00, A61K 7/50, G01N 21/31, A61K 7/48

(21) International Application Number: PCT/US01/11860

(22) International Filing Date: 11 April 2001 (11.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/547,433 12 April 2000 (12.04.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/547,433 (CIP)
Filed on 12 April 2000 (12.04.2000)

(71) Applicant (for all designated States except US): MEDOPTIX, INC. [US/US]; 10011 N. Foothill Blvd., Suite 107, Cupertino, CA 95014 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): BERMAN, Herbert, Published: — with international search report

L. [US/US]; 12680 Viscaino Road, Los Altos Hills, CA 94022 (US). ROE, Jeffrey, N. [US/US]; 3212 Veracruz Drive, San Ramon, CA 94583 (US).


(74) Agents: HAN, Johnney, U. et al.; Morrison & Foerster, LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: INFRARED ATR GLUCOSE MEASUREMENT SYSTEM



WO 01/079818 A3



(57) Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.



(88) Date of publication of the international search report:

18 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

In...national Application No
PCT/US 01/11860

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N21/55 G01N21/35 A61B5/00 A61K7/50 G01N21/31
A61K7/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N A61B A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 404 562 A (HAALAND DAVID MICHAEL ;WARD KENNETH JOHN (US); UNIV NEW MEXICO (US) 27 December 1990 (1990-12-27)	71-74
Y	column 6, line 10 - line 36 column 8, line 51 - line 58 column 9, line 28 - line 54 column 11, line 25 - line 31 column 11, line 35 - line 38 column 12, line 2 - line 32 column 13, line 5 - line 8 ---	1-3, 10-20, 23, 26-48,61

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

25 March 2002

04.04.02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Navas Montero, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/11860

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 169 676 A (KAISER NILS) 2 October 1979 (1979-10-02) cited in the application column 2, line 33 - line 58 column 4, line 22 - line 28 column 4, line 36 -column 5, line 19	1-3, 10-20, 23, 26-48,61
X,P	WO 00 21437 A (ROE JEFFREY N ;BERMAN HERBERT L (US)) 20 April 2000 (2000-04-20) cited in the application the whole document	1-48, 61-74
A	US 5 935 062 A (MESSERSCHMIDT ROBERT G ET AL) 10 August 1999 (1999-08-10) the whole document	68
Y	US 5 786 892 A (MILES STEVE ET AL) 28 July 1998 (1998-07-28) column 2, line 32 - line 67	49-60
Y	US 5 962 441 A (BLANK ROY LONNIE) 5 October 1999 (1999-10-05) column 1, line 40 - line 42 column 4, line 8 - line 21 column 4, line 33 - line 46 column 6, line 1 - line 6 column 6, line 11 - line 14 column 6, line 51 - line 61 column 11, line 66 -column 12, line 11	49-60
Y	US 4 071 020 A (PUGLIESE PETER) 31 January 1978 (1978-01-31) column 1, line 6 - line 21 column 3, line 3 - line 13 column 5, line 61 -column 6, line 8	49-60
Y	EP 0 355 368 A (ORION YHTYMAE OY) 28 February 1990 (1990-02-28) page 2, line 1 - line 3 page 2, line 22 - line 27	49-60
X,P	WO 00 57177 A (WEITMAN IRWIN ;MITCHEN JOEL R (US); WEISS JOHN (US); ARONOWITZ JAC) 28 September 2000 (2000-09-28) page 24, line 20 -page 25, line 14	49
A	US 5 470 323 A (SMITH JAMES A ET AL) 28 November 1995 (1995-11-28) the whole document	55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/11860

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-48 61-74

An analyte level measurement device.

2. Claims: 49-60

A cleaning kit.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In...national Application No

PCT/US 01/11860

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0404562	A 27-12-1990	US	4975581 A	04-12-1990
		AT	169406 T	15-08-1998
		AU	638649 B2	01-07-1993
		AU	5771490 A	03-01-1991
		CA	2019511 A1	21-12-1990
		DE	69032535 D1	10-09-1998
		DE	69032535 T2	10-12-1998
		EP	0404562 A2	27-12-1990
		IL	94822 A	15-03-1995
		JP	2965212 B2	18-10-1999
		JP	3114441 A	15-05-1991
		ZA	9004805 A	27-03-1991
US 4169676	A 02-10-1979	DE	2606991 A1	25-08-1977
		BE	851606 A1	16-06-1977
		CA	1084300 A1	26-08-1980
		CH	612271 A5	13-07-1979
		FR	2341866 A1	16-09-1977
		GB	1531375 A	08-11-1978
		IT	1071579 B	10-04-1985
		JP	52102094 A	26-08-1977
		LU	76810 A1	06-07-1977
		NL	7701778 A	23-08-1977
		SE	7701901 A	21-08-1977
WO 0021437	A 20-04-2000	AU	6428699 A	01-05-2000
		EP	1137364 A2	04-10-2001
		NO	20011815 A	07-06-2001
		WO	0021437 A2	20-04-2000
US 5935062	A 10-08-1999	US	5636633 A	10-06-1997
		US	6230034 B1	08-05-2001
		US	2001021802 A1	13-09-2001
		CA	2229065 A1	20-02-1997
		CN	1198814 A	11-11-1998
		EP	0845103 A1	03-06-1998
		JP	11510602 T	14-09-1999
		WO	9706425 A1	20-02-1997
US 5786892	A 28-07-1998	GB	2288461 A	18-10-1995
		AT	176725 T	15-02-1999
		DE	69507796 D1	25-03-1999
		DE	69507796 T2	17-06-1999
		EP	0754297 A1	22-01-1997
		ES	2127519 T3	16-04-1999
		WO	9527892 A1	19-10-1995
		JP	9511580 T	18-11-1997
US 5962441	A 05-10-1999	US	5691327 A	25-11-1997
		US	5616572 A	01-04-1997
		US	5801163 A	01-09-1998
		US	5795879 A	18-08-1998
		US	5756487 A	26-05-1998
		US	5840717 A	24-11-1998
		US	5872112 A	16-02-1999
		US	5780457 A	14-07-1998
		US	5786346 A	28-07-1998
		US	5843926 A	01-12-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/11860

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
US 5962441	A	US	5595984 A	21-01-1997	
		US	5573759 A	12-11-1996	
		US	5604212 A	18-02-1997	
		US	5597813 A	28-01-1997	
		US	5597814 A	28-01-1997	
		US	5652229 A	29-07-1997	
		US	5620965 A	15-04-1997	
		US	5629301 A	13-05-1997	
		US	5652230 A	29-07-1997	
		US	5780456 A	14-07-1998	
		US	5780458 A	14-07-1998	
		AT	198702 T	15-02-2001	
		AU	3073792 A	28-06-1993	
		CA	2122271 A1	10-06-1993	
		DE	69231647 D1	22-02-2001	
		DE	69231647 T2	02-08-2001	
		EP	0614354 A1	14-09-1994	
		EP	0958810 A2	24-11-1999	
		ES	2153366 T3	01-03-2001	
		JP	7501541 T	16-02-1995	
		MX	9206794 A1	01-11-1993	
		PT	101092 A	28-02-1994	
		WO	9310756 A1	10-06-1993	
US 4071020		A	31-01-1978	NONE	
EP 0355368	A	28-02-1990	FI	883310 A	13-01-1990
			AT	101030 T	15-02-1994
			CA	1335875 A1	13-06-1995
			DE	68912848 D1	17-03-1994
			DK	339489 A	13-01-1990
			EP	0355368 A2	28-02-1990
			NO	892849 A	15-01-1990
WO 0057177	A	28-09-2000	US	5021185 A	04-06-1991
			AU	4005700 A	09-10-2000
US 5470323	A	28-11-1995	WO	0057177 A1	28-09-2000
			US	5242433 A	07-09-1993
			CA	2151122 A1	23-06-1994
			EP	0746377 A1	11-12-1996
			WO	9413354 A1	23-06-1994
			US	5460620 A	24-10-1995

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/79818 A2

(51) International Patent Classification²: G01N 21/55,
21/35, A61B 5/00, A61K 7/50 94022 (US). ROE, Jeffrey, N. [US/US]; 3212 Veracruz
Drive, San Ramon, CA 94583 (US).

(21) International Application Number: PCT/US01/11860

(74) Agents: HAN, Johny, U. et al.; Morrison & Foerster,
LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(22) International Filing Date: 11 April 2001 (11.04.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
09/547,433 12 April 2000 (12.04.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 09/547,433 (CIP)
Filed on 12 April 2000 (12.04.2000)

Published:
— without international search report and to be republished
upon receipt of that report

(71) Applicant (for all designated States except US): MEDOPTIX, INC. [US/US]; 10011 N. Foothill Blvd., Suite 107,
Cupertino, CA 95014 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and
(75) Inventors/Applicants (for US only): BERMAN, Herbert,
L. [US/US]; 12680 Viscaino Road, Los Altos Hills, CA

WO 01/79818 A2

(54) Title: INFRARED ATR GLUCOSE MEASUREMENT SYSTEM (II)

(57) Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.

INFRARED ATR GLUCOSE MEASUREMENT SYSTEM (II)**Related Applications**

5 This is a continuation-in-part of PCT/US99/23823, filed October 12, 1999, designating the U.S., which in turn is derives benefit from U.S. App. Ser. No. 60/103,883, to Berman and Roe, filed October 13, 1998.

Field of the Invention

10 This invention involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The inventive device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip or
15 other part of the body. Although the inventive procedure preferably compares two specific regions of a measured mid-infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other materials which exhibit unique mid-IR signatures of the
20 type described below and that are found in appropriate regions of the outer skin. A cleaning kit and related procedure for preparation of the skin surface is also included.

Background of the Invention

25 The American Diabetes Association reports that nearly 6% of the population in the United States, a group of 16 million people, has diabetes. The Association further reports that diabetes is the seventh leading cause of death in the United States, contributing to nearly 200,000 deaths per year. Diabetes is a chronic disease having no cure. The complications of the disease include blindness, kidney disease, nerve disease, and heart disease, perhaps with stroke. Diabetes is said to be the leading cause of new cases of
30 blindness in individuals in the range of ages between 20 and 74; from 12,000-24,000 people per year lose their sight because of diabetes. Diabetes is the leading cause of end-

stage renal disease, accounting for nearly 40% of new cases. Nearly 60-70% of people with diabetes have mild to severe forms of diabetic nerve damage which, in severe forms, can lead to lower limb amputations. People with diabetes are 2-4 times more likely to have heart disease and to suffer strokes.

5 Diabetes is a disease in which the body does not produce or properly use insulin, a hormone needed to convert sugar, starches, and the like into energy. Although the cause of diabetes is not completely understood, genetics, environmental factors, and viral causes have been partially identified.

10 There are two major types of diabetes: Type I and Type II. Type I diabetes (formerly known as juvenile diabetes) is an autoimmune disease in which the body does not produce any insulin and most often occurs in young adults and children. People with Type I diabetes must take daily insulin injections to stay alive.

15 Type II diabetes is a metabolic disorder resulting from the body's inability to make enough, or properly to use, insulin. Type II diabetes accounts for 90-95% of diabetes. In the United States, Type II diabetes is nearing epidemic proportions, principally due to an increased number of older Americans and a greater prevalence of obesity and a sedentary lifestyle.

20 Insulin, in simple terms, is the hormone that unlocks the cells of the body, allowing glucose to enter those cells and feed them. Since, in diabetics, glucose cannot enter the cells, the glucose builds up in the blood and the body's cells literally starve to death.

25 Diabetics having Type I diabetes typically are required to self-administer insulin using, e.g., a syringe or a pen with needle and cartridge. Continuous subcutaneous insulin infusion via implanted pumps is also available. Insulin itself is typically obtained from pork pancreas or is made chemically identical to human insulin by recombinant DNA technology or by chemical modification of pork insulin. Although there are a variety of different insulins for rapid-, short-, intermediate-, and long-acting forms that may be used variously, separately or mixed in the same syringe, use of insulin for treatment of diabetes is not to be ignored.

30 It is highly recommended by the medical profession that insulin-using patients practice self-monitoring of blood glucose (SMBG). Based upon the level of glucose in the blood, individuals may make insulin dosage adjustments before injection. Adjustments are necessary since blood glucose levels vary day to day for a variety of reasons, e.g., exercise,

stress, rates of food absorption, types of food, hormonal changes (pregnancy, puberty, etc.) and the like. Despite the importance of SMBG, several studies have found that the proportion of individuals who self-monitor at least once a day significantly declines with age. This decrease is likely due simply to the fact that the typical, most widely used, 5 method of SMBG involves obtaining blood from a finger stick. Many patients consider obtaining blood to be significantly more painful than the self-administration of insulin.

There is a desire for a less invasive method of glucose measurement. Methods exist or are being developed for a minimally invasive glucose monitoring, which use body fluids other than blood (e.g., sweat or saliva), subcutaneous tissue, or blood measured less 10 invasively. Sweat and saliva are relatively easy to obtain, but their glucose concentration appears to lag in time significantly behind that of blood glucose. Measures to increase sweating have been developed and seem to increase the timeliness of the sweat glucose measurement, however.

Subcutaneous glucose measurements seem to lag only a few minutes behind 15 directly measured blood glucose and may actually be a better measurement of the critical values of glucose concentrations in the brain, muscle, and in other tissue. Glucose may be measured by non-invasive or minimally-invasive techniques, such as those making the skin or mucous membranes permeable to glucose or those placing a reporter molecule in the subcutaneous tissue. Needle-type sensors have been improved in accuracy, size, and 20 stability and may be placed in the subcutaneous tissue or peripheral veins to monitor blood glucose with small instruments. See, *"An Overview of Minimally Invasive Technologies"*, Clin. Chem. 1992 Sep.; 38(9):1596-1600.

Truly simple, non-invasive methods of measuring glucose are not commercially 25 available.

U.S. Patent No. 4,169,676 to Kaiser, shows a method for the use of ATR glucose measurement by placing the ATR plate directly against the skin and especially against the tongue. The procedure and device shown there uses a laser and determines the content of 30 glucose in a specific living tissue sample by comparing the IR absorption of the measured material against the absorption of IR in a control solution by use of a reference prism. See, column 5, lines 31 et seq.

Swiss Patent No. 612,271, to Dr. Nils Kaiser, appears to be the Swiss patent corresponding to U.S. Patent No. 4,169,676.

U.S. Patent No. 4,655,255, to Dähne et al., describes an apparatus for non-invasively measuring the level of glucose in a blood stream or tissues of patients suspected to have diabetes. The method is photometric and uses light in the near-infrared region. Specifically, the procedure uses light in the 1,000 to 2,500 nm range. Dähne's device is 5 jointly made up to two main sections, a light source and a detector section. They may be situated about a body part such as a finger. The desired near-infrared light is achieved by use of filters. The detector section is made up of a light-collecting integrating sphere or half-sphere leading to a means for detecting wavelengths in the near-infrared region. Dähne et al. goes to some lengths teaching away from the use of light in the infrared range 10 having a wavelength greater than about 2.5 micrometers since those wavelengths are strongly absorbed by water and have very little penetration capability into living tissues containing glucose. That light is said not to be "readily useable to analyze body tissue volumes at depths exceeding a few microns or tens of microns." Further, Dähne et al. specifically indicates that an ATR method which tries to circumvent the adverse 15 consequences of the heat effect by using a total internal reflection technique is able only to investigate to tissue depths not exceeding about 10 micrometers, a depth which is considered by Dähne et al. to be "insufficient to obtain reliable glucose determination information."

U.S. Patent No. 5,028,787, to Rosenthal et al., describes a non-invasive glucose 20 monitoring device using near-infrared light. The light is passed into the body in such a way that it passes through some blood-containing region. The so-transmitted or reflected light is then detected using an optical detector. The near-infrared light sources are preferably infrared emitting diodes (IRED). U.S. Patent No. 5,086,229 is a continuation in part of U.S. Patent No. 5,028,787.

U.S. Patent No. 5,178,142, to Harjunmaa et al, teaches the use of a stabilized near-infrared radiation beam containing two alternating wavelengths in a device to determine a concentration of glucose or other constituents in a human or animal body. Interestingly, one of the transmitted IR signals is zeroed by variously tuning one of the wavelengths, changing the extracellular to intracellular fluid ratio of the tissue by varying the mechanical 25 pressure on a tissue. Or, the ratio may be allowed to change as a result of natural pulsation, e.g., by heart rate. The alternating component of the transmitted beam is measured in the "change to fluid ratio" state. The amplitude of the varying alternating signal is detected

and is said to represent glucose concentration or is taken to represent the difference in glucose concentration from a preset reference concentration.

U.S. Patent No. 5,179,951 and its divisional, U.S. Patent No. 5,115,133, to Knudson, show the application of infrared light for measuring the level of blood glucose in blood vessels in the tympanic membrane. The detected signal is detected, amplified, decoded, and, using a microprocessor, provided to a display device. The infrared detector (No. 30 in the drawings) is said simply to be a "photo diode and distance signal detector" which preferably includes "means for detecting the temperature of the volume in the ear between the detector and the ear's tympanic membrane." Little else is said about the 10 constituency of that detector.

U.S. Patent No. 5,433,197, to Stark, describes a non-invasive glucose sensor. The sensor operates in the following fashion. A near-infrared radiation is passed into the eye through the cornea and the aqueous humor, reflected from the iris or the lens surface, and then passed out through the aqueous humor and cornea. The reflected radiation is collected 15 and detected by a near-infrared sensor which measures the reflected energy in one or more specific wavelength bands. Comparison of the reflected energy with the source energy is said to provide a measure of the spectral absorption by the eye components. In particular, it is said that the level of glucose in the aqueous humor is a function of the level of glucose in the blood. It is said in Stark that the measured glucose concentration in the aqueous humor 20 tracks that of the blood by a fairly short time, e.g., about 10 minutes. The detector used is preferably a photodiode detector of silicon or InGaAs. The infrared source is said preferably to be an LED, with a refraction grating so that the light of a narrow wavelength band, typically 10 to 20 nanometers wide, passes through the exit slit. The light is in the near-infrared range. The use of infrared regions below 1400 nanometers and in the region 25 between 1550 and 1750 nanometers is suggested.

U.S. Patent No. 5,267,152, to Yang et al., shows a non-invasive method and device for measuring glucose concentration. The method and apparatus uses near-infrared radiation, specifically with a wavelength of 1.3 micrometers to 1.8 micrometers from a semiconductor diode laser. The procedure is said to be that the light is then transmitted 30 down through the skin to the blood vessel where light interacts with various components of the blood and is then diffusively reflected by the blood back through the skin for measurement.

Similarly, U.S. Patent No. 5,313,941, to Braig et al., suggests a procedure and apparatus for monitoring glucose or ethanol and other blood constituents in a non-invasive fashion. The measurements are made by monitoring absorption of certain constituents in the longer infrared wavelength region. The long wavelength infrared energy is passed through the finger or other vascularized appendage. The infrared light passing through the finger is measured. The infrared source is pulsed to prevent burning or other patient discomfort. The bursts are also synchronized with the heartbeat so that only two pulses of infrared light are sent through the finger per heartbeat. The detected signals are then analyzed for glucose and other blood constituent information.

10 U.S. Patent No. 5,398, 681, to Kuperschmidt, shows a device which is said to be a pocket-type apparatus for measurement of blood glucose using a polarized-modulated laser beam. The laser light is introduced into a finger or ear lobe and the phase difference between a reference signal and the measurement signal is measured and processed to formulate and calculate a blood glucose concentration which is then displayed.

15 U.S. Patent No. 6,001,067 shows an implantable device suitable for glucose monitoring. It utilizes a membrane which is in contact with a thin electrolyte phase, which in turn is covered by an enzyme-containing membrane, e.g., glucose oxidase in a polymer system. Sensors are positioned in such a way that they measure the electro-chemical reaction of the glucose within the membranes. That information is then passed to the 20 desired source.

None of the cited prior art suggests the device and method of using this device described and claimed below.

SUMMARY OF THE INVENTION

25 This invention is a glucose level measurement device utilizing IR-ATR spectroscopy and a method of using the device. The inventive device itself is preferably made up of four parts:

- a.) an IR source for emitting an IR beam into the ATR plate,
- b.) the ATR plate against which the sampled human skin surface is pressed, and
- c.) at least two IR sensors for simultaneously measuring absorbance of two specific regions of the IR spectrum, i.e., a "referencing wavelength" and a "measuring

wavelength." The IR source must emit IR radiation at least in the region of the referencing wavelength and the measuring wavelength. For glucose, the referencing wavelength is between about 8.25 micrometers and about 8.75 micrometers and the measuring wavelength is between about 9.50 micrometers and about 10.00 micrometers. The IR sources may be broadband IR sources, non-laser sources, or two or more selected wavelength lasers.

Other analyte materials which have both referencing wavelengths and measuring wavelengths as are described in more detail below and that preferably are found in the outer regions of the skin may be measured using the inventive devices and procedures described herein.

The ATR plate is configured to permit multiple internal reflections, perhaps 3-15 internal reflections or more, against said measurement surface prior to measurement by the IR sensors. Typically the IR beam emitted from the ATR plate is split for the IR sensors using a beam splitter or equivalent optical device. Once the split beams are measured by the IR sensors, the resulting signals are then transformed using analog comparators or digital computers into readable or displayable values.

It is usually important that the device have some accommodation for holding the body part against the ATR plate, preferably at some value which is constant and above a selected minimum pressure.

The method for determining the blood glucose level, using the glucose measurement device, comprises the steps of:

- a.) contacting a selected skin surface with the ATR plate,
- b.) irradiating that human skin surface with an IR beam having components at least in the region of the referencing wavelength and the measuring wavelength, and
- c.) detecting and quantifying those referencing and said measuring wavelength components in that reflected IR beam.

The procedure ideally includes the further steps of maintaining the skin surface on said ATR plate at an adequate pressure which is both constant and above a selected minimum pressure and, desirably cleaning the skin surface before measurement. A step of actually measuring the pressure may also be included.

A normalizing step practiced by simultaneously detecting and quantifying the referencing and measuring wavelength components prior to contacting the skin surface is also desirable.

5 A final portion of this invention is a cleaning kit used for cleaning the object skin prior to testing and a process of using that kit. The kit usually is made up of sealed packets, preferably containing absorbent pads, of:

- a.) a glucose solvent, e.g., water and/or other highly polar solvent and perhaps containing a weak acid,
- b.) a solvent for removing the glucose solvent, e.g., isopropanol, and
- 10 c.) a skin softener or pliability enhancer, e.g., various mineral oils such as "Nujol", not having significant IR wavelength peaks between about 8.25 micrometers and about 8.75 micrometers or between about 9.50 micrometers and about 10.00 micrometers. I prefer to mix components b.) and c.). The solvent for removing the glucose solvent similarly should not have an interfering IR signal which persists after several minutes.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A, 1B, 1C, and 1D show a side view of various ATR plates and their general operation.

20

Figure 2 shows an IR spectrum of d-glucose.

Figure 3 shows a schematicized layout of the optics of the inventive device.

Figure 4 shows a packaged variation of the inventive glucose measuring device.

Figure 5 shows a graph of pressure on the ATR crystal vs. IR value.

Figure 6 shows a graph correlating glucose levels measured using a specific variation of the device with glucose levels in the blood determined using a commercial device.

25

Figure 7 shows a graph using a transmittance trough as the referencing wavelength.

Figure 8 shows a pair of glucose IR curves (taken before and after eating) for an individual having diabetes made using the inventive glucose measuring device.

30

Figure 9 shows a graph comparing glucose levels in a non-diabetic individual (taken before and after eating) made using the inventive glucose measuring device and direct blood measurement. This graph shows that the inventive procedure tracks blood glucose levels with minimum time lag.

DESCRIPTION OF THE INVENTION

The device in this invention uses infrared ("IR") attenuated total reflectance ("ATR") spectroscopy to detect and ultimately to determine the level of a selected analyte, preferably blood glucose, in the human body. Preferably, the inventive device uses an ATR procedure in which the size and configuration of the crystal permits a number of internal reflections before the beam is allowed to exit the crystal with its measured information. In general, as shown in Figures 1A and 1B, when an infrared beam (102) is incident on the upper surface of the ATR crystal (104) -- or ATR plate -- at an angle which exceeds a critical angle Θ_C , the beam (102) will be completely totally reflected within crystal (104). Each reflection of the beam within the ATR plate, and specifically against the upper surface (114), provides a bit more information about the composition of the sample (112) resting against that upper surface (114). The more numerous the reflections, and the greater the penetration depth of the reflection, the higher is the quality of the information. The incident beam (102) becomes reflected beam (106) as it exits crystal (104) as shown in Figure 1A. Higher refractive index materials are typically chosen for the ATR crystal to minimize the critical angle. The critical angle is a function of the refractive indices of both the sample and the ATR crystal and is defined as:

$$\Theta_C = \sin^{-1} \left(\frac{n_2}{n_1} \right)$$

Here, n_1 is the refractive index of the ATR crystal and n_2 is the refractive index of the sample.

Throughout this specification, we refer to wavelength measures as specific values. It should be understood that we intend those values to be bands or ranges of values, typically with a tolerance of +/- 0.20 micron, preferably +/- 0.10 micron. For instance, a value of 8.25 microns would mean a band of 8.15 to 8.35 microns, and perhaps 8.05 to 8.45 microns depending upon the context.

As shown in Figure 1B, the internally reflected beam (108) includes an evanescent wave (110) which penetrates a short distance into sample (112) over a wide wavelength range. In those regions of the IR spectrum in which the sample absorbs IR, some portion of

the light does not return to the sensor. It is these regions of IR absorbance which provide information, in this inventive device, for quantification of the glucose level.

We have found that the mid-IR spectrum does not penetrate into the skin to an appreciable level. Specifically, the skin is made up of a number of layers: the outermost -- 5 the *stratum corneum* -- is a layer substantially free of cholesterol, water, gamma globulin, albumin, and blood. It is a shallow outer region covering the *stratum granulosum*, the *stratum spinosum*, and the basal layer. The area between the basal layer to the outside is not vascularized. It is unlikely that any layer other than the *stratum corneum* is traversed by the mid-IR light involved in this inventive device. Although we do not wish to be 10 bound by theory, it is likely that the eccrine or sweat glands transport the glucose to the outer skin layers for measurement and analysis by our inventions.

We prefer the use of higher refractive index crystals such as zinc selenide, zinc sulfide, diamond, germanium, and silicon as the ATR plate. The index of refraction of the ATR plate (104) should be significantly higher than that of the sample (112).

15 Further, the ATR crystal (104) shown in Figure 1A is shown to be trapezoidal and having an upper surface (114) for contact with the sample, which sample, in this case, is skin from a living human body. However, this shape is only for the purposes of mechanical convenience and ease of application into a working commercial device. Other shapes, in 20 particular, a parallelogram (111) such as shown in Figure 1C and the reflective crystal (113) shown in Figure 1D having mirrored end (115), are also quite suitable for this inventive device should the designer so require. The mirrored reflective crystal (113) has the advantage of, and perhaps the detriment of having both an IR source and the IR sensors 25 at the same end of the crystal.

It is generally essential that the ATR crystal or plate (104) have a sample or upper 25 surface (114) which is essentially parallel to the lower surface (116). In general, the ATR plate (104) is preferably configured and utilized so that the product of the practical number of internal reflections of internal reflected beam (108) and the skin penetration per reflection of this product is maximized. When maximizing this product, called the effective pathlength (EPL), the information level in beam (106) as it leaves ATR plate 30 (104) is significantly higher. Further, the higher the value of the index of refraction, n_2 , of the ATR plate (104), the higher is the number of internal reflections. The sensitivity of the IR sensors also need not be as high when the EPL is maximized. We consider the number

of total reflections within the crystal to be preferably from 3-15 or more for adequate results.

We have surprisingly found that a glucose measuring device made according to this invention is quite effective on the human skin of the hands and fingers. We have found that 5 the glucose concentration as measured by the inventive devices correlates very closely with the glucose concentration determined by a direct determination from a blood sample. As will be discussed below, the glucose level as measured by the inventive device also is surprisingly found closely to track the glucose level of blood in time as well. This is surprising in that the IR beam likely passes into the skin, i.e., the *stratum corneum*, for only 10 a few microns. It is unlikely in a fingertip that any blood is crossed by that light path. As discussed above, the *stratum corneum* is the outer layer of skin and is substantially unvascularized. The *stratum corneum* is the final outer product of epidermal differentiation or keratinization. It is made up of a number of closely packed layers of flattened polyhedral corneocytes (also known as squames). These cells overlap and interlock with 15 neighboring cells by ridges and grooves. In the thin skin of the human body, this layer may be only a few cells deep, but in thicker skin, such as may be found on the toes and feet, it may be more than 50 cells deep. The plasma membrane of the corneocyte appears thickened compared with that of keratinocytes in the lower layers of the skin, but this apparent deposition of a dense marginal band formed by stabilization of a soluble 20 precursor, involucrin, just below the *stratum corneum*.

It is sometimes necessary to clean the skin exterior prior before sampling to remove extraneous glucose from the skin surface. When doing so, it is important to select cleaning materials which have IR spectra that do not interfere with the IR spectra of glucose. We consider a kit of the following to be suitable for preparation of the sample skin for the 25 testing. The components are: a.) a glucose solvent, e.g., water or other highly polar solvent; b.) a solvent for removing the water, e.g., isopropanol, and c.) a skin softener or pliability enhancer not having significant IR peaks in the noted IR regions, e.g., mineral oils such as those sold as "Nujol". Preferably the b.) and c.) components are admixed, although they need not be. Certain mixtures of the first two components may be 30 acceptable, but only if the sampling situation is such that the solvents evaporate without spectrographically significant residue. We have also found that soap and its residue are sometimes a problem. Consequently, addition of a weak acid again not having significant

IR peaks in the noted IR regions, to the a.) component, i.e., the solvent for removing glucose, is desirable. The preferred weak acid is boric acid. The inventive kit preferably is made up of sealed packets of the components, most preferably each packet containing an absorbent pad.

5 Additionally, the inventive device can be highly simplified compared to other known devices in that the device can be "self-normalizing" due to the specifics of the IR signature of glucose. Figure 2 shows the IR absorbance spectra of d-glucose. The family of curves there shows that in certain regions of the IR spectrum, there is a correlation between absorbance and the concentration of glucose. Further, there is a region in which
10 the absorbance is not at all dependent upon the concentration of glucose. Our device, in its preferable method of use, uses these two regions of the IR spectra. These regions are in the so-called mid-IR range, i.e., wavelengths between 2.5 and 14 micrometers. In particular, the "referencing wavelength" point is just above 8 micrometers (150), e.g., 8.25 to 8.75 micrometers, and the pronounced peaks (152) at the region between about 9.50 and 10.00
15 micrometers is used as a "measuring wavelength". The family of peaks (152) may be used to determine the desired glucose concentration.

Use of the two noted IR regions is also particularly suitable since other components typically found in the skin, e.g., water, cholesterol, etc., do not cause significant measurement error when using the method described herein.

20 Figure 3 shows an optical schematic of a desired variation of the inventive device. ATR crystal (104) with sample side (114) is shown and IR source (160) is provided. IR source (160) may be any of a variety of different kinds of sources. It may be a broadband IR source, one having radiant temperatures of 300°C to 800°C, or a pair of IR lasers selected for the two regions of measurement discussed above, or other suitably emitted or
25 filtered IR light sources. A single laser may not be a preferred light source in that a laser is a single wavelength source and the preferred operation of this device requires light sources simultaneously emitting two IR wavelengths. Lens (162), for focusing light from IR source (160) into ATR plate (104), is also shown. It may be desirable to include an additional mirror (163) to intercept a portion of the beam before it enters the ATR plate (104) and
30 then to measure the strength of that beam in IR sensor (165). Measurement of that incident light strength (during normalization and during the sample measurement) assures that any changes in that value can be compensated for.

The light then passes into ATR plate (104) for contact with body part (164), shown in this instance to be the desired finger. The reflected beam (106) exits ATR plate (104) and is then desirably split using beam splitter (166). Beam splitter (166) simply transmits some portion of the light through the splitter and reflects the remainder. The two beams 5 may then be passed through, respectively, lenses (168) and (170). The so-focussed beams are then passed to a pair of sensors which are specifically selected for detecting and measuring the magnitude of the two beams in the selected IR regions. Generally, the sensors will be made up of filters (172) and (174) with light sensors (176) and (178) behind. Generally, one of the filters (172), (174) will be in the region of the referencing 10 wavelength and the other will be in that of the measuring wavelength.

Figure 4 shows perhaps a variation of this device (200) showing the finger of the user (202) over the ATR plate (204) with a display (206). Further shown in this desirable variation (200) is a pressure maintaining component (208). We have found that is very highly desirable to maintain a minimum threshold pressure on the body part which is to be 15 used as the area to be measured. Generally, a variance in the pressure does not shift the position of the detected IR spectra, but it may affect the sensitivity of the overall device. Although it is possible to teach the user to press hard enough on the device to reach the minimum threshold pressure, we have determined for each design of the device it is much more appropriate that the design of a particular variation of the inventive device be 20 designed with a specific sample pressure in mind: The appropriate pressure will vary with, e.g., the size of the ATR plate and the like. A constant pressure above that minimum threshold value is most desired.

The variation shown in Figure 4 uses a simple component arm (208) to maintain 25 pressure of the finger (202) on ATR plate (204). Other variations within the scope of this invention may include clamps and the like.

It should be apparent that once an appropriate pressure is determined for a specific design, the inventive device may include a pressure sensor, e.g., (210) as is shown in Figure 4, to measure adherence to that minimum pressure. Pressure sensor (210) may alternatively be placed beneath ATR plate (204). It is envisioned that normally a pressure sensor such as 30 (210) would provide an output signal which would provide a "no-go/go" type of signal to the user.

Further, as shown in Figure 5, the appropriate pressure may be achieved when using our device simply by increasing the pressure of the body part on the ATR crystal surface until a selected, measured IR value becomes constant.

5 Method of Use

In general, the inventive device described above is used in the following manner: a skin surface on a human being, for instance, the skin of the finger, is placed on the ATR plate. The skin surface is radiated with an IR beam having components at least in the two IR regions we describe above as the "referencing wavelength" and the "measuring wavelength." The beam which ultimately is reflected out of the ATR plate then contains information indicative of the blood glucose level in the user. As noted above, it is also desirable to maintain that skin surface on the ATR plate at a relatively constant pressure that is typically above a selected minimum pressure. This may be done manually or by measuring and maintaining the pressure or monitoring the constancy of a selected IR value.

10 Typically, the beam leaving the ATR plate is split using an optical beam splitter into at least two beams. Each of the two beams may be then focussed onto its own IR sensor. Each such IR sensor has a specific filter. This is to say that, for instance, one IR sensor may have a filter which removes all light which is not in the region of the referencing wavelength and the other IR sensor would have a filter which remove all wavelengths other than those in the region of the measuring wavelength. As noted above, for glucose, the referencing wavelength is typically in the range of about 8.25 to 8.75 micrometers. For glucose, the measuring wavelength is typically between about 9.5 and 10.0 micrometers.

15 Other analyte materials which have both referencing wavelengths and measuring wavelengths in the mid-IR range and that are found in the outer regions of the skin may also be measured using the inventive devices and procedures described herein.

20 Respective signals may be compared using analog or digital computer devices. The signals are then used to calculate analyte values such as blood glucose concentration using various stored calibration values, typically those which are discussed below. The resulting calculated values may then be displayed.

25 As noted above, it is also desirable both to clean the plate before use and to clean the exterior surface of the skin to be sampled. Again, we have found, for instance in the

early morning that the exterior skin is highly loaded with glucose which is easily removed preferably by using the skin preparation kit, or, less preferably, by washing the hands.

Reproducible and accurate glucose measurements may then be had in a period as short as ten minutes after cleaning the area of the skin to be measured.

5 We also note that, depending upon the design of a specific variation of a device made according to the invention, periodic at least an initial calibration of the device, using typical blood sample glucose determinations, may be necessary or desirable.

10 Determination of blood glucose level from the information provided in the IR spectra is straightforward. A baseline is first determined by measuring the level of infrared absorbance at the measuring and referencing wavelengths, without a sample being present on the sample plate. The skin is then placed in contact with the ATR plate and the two specified absorbance values are again measured. Using these four values, the following calculation is then made.

15
$$A_1 = \ln\left(\frac{T_{01}}{T_1}\right) = A_{g1} + A_{b1} \quad (\text{Absorbance at referencing spectral band.})$$

$$A_2 = \ln\left(\frac{T_{02}}{T_2}\right) = A_{g2} + A_{b2} \quad (\text{Absorbance at measuring spectral band.})$$

where: T_{01} = measured value at reference spectral band w/o sample

T_{02} = measured value at measuring spectral band w/o sample

20 T_1 = measured value at reference spectral band w/ sample

T_2 = measured value at measuring spectral band w/ sample

A_{g1} = absorbance of glucose at reference spectral band

A_{g2} = absorbance of glucose at measuring spectral band

A_{b1} = absorbance of background at reference spectral band

25 A_{b2} = absorbance of background at measuring spectral band

d = effective path length through the sample.

a_2 = specific absorptivity at measuring spectral band

k = calibration constant for the device

C_g = measured concentration of glucose

Since the background base values are approximately equal (i.e., $A_{b1} = A_{b2}$) and $A_{g1} = 0$, then:

5

$$A_2 - A_1 = A_{g2} = a_2 d C_g$$

and

$$C_g = k(A_2 - A_1)$$

10

The value of C_g is the desired result of this procedure.

Similarly, Figure 7 shows a graph in which the value of the analyte is assessed using similar calculations but in which the "referencing wavelength" is an absorbance trough ("b") unaffected by the concentration of the analyte. The "measuring wavelength" peak ("a") is measured against a baseline.

EXAMPLES

20 Example 1

Using a commercially available IR spectrometer (Nicolet 510) having a ZnSe crystal ATR plate (55mm long, 10mm wide, and 4mm thick) we tested the inventive procedure. We calibrated the output of the spectrometer by comparing the IR signal to the values actually measured using one of the inventor's blood samples. The inventor used a blood stick known as "Whisper Soft" by Amira Medical Co. and "Glucometer Elite" blood glucose test strips sold by Bayer Corp. of Elkhart, Ind. On each of the various test days, the inventor took several test sticks and measured the glucose value of the resulting blood; the IR test was made at the same approximate time.

As shown in the calibration curve of Figure 6, the data are quite consistent. So, 30 where the blood glucose concentration "B" is in (mg/dl) and "S" is the difference between

the absorbance at the referencing region and the measuring region as measured by the spectrometer:

$$B = [(1950) \bullet S] - (17).$$

5

Example 2

In accordance with a clinical protocol, a diabetic was then tested. Curve 1 in Figure 8 shows the IR absorbance spectrum of the test subject's finger before eating (and after fasting overnight) and curve 2 shows IR absorbance spectrum of the same individual after having eaten. Incidentally, insulin was administered shortly after the measurement of curve 2.

10

In any event, the significant difference in the two peak heights at the 9.75 micrometer wavelength and the equality of the two IR absorbance values at the 8.50 micrometer value shows the effectiveness of the procedure in measuring glucose level.

15

Example 3

That the inventive glucose monitoring device non-invasively determines blood glucose level and quickly follows changes in that blood glucose level is shown in Figure 9. Using both the inventive procedure and a commercial glucose device, one of the inventors followed his glucose level for a single day. The blood sticks are considered to be accurate within 15% of the actual reading.

20

The results are shown in Figure 9. Of particular interest is the measurement just before 4:40pm wherein the two values are essentially the same. A high sugar candy bar was eaten at about 4:45pm and measurements of glucose level were taken using the inventive procedure at about 5:03, 5:18, 5:35 and 5:50. A blood sample was taken at 5:35 and reflected almost the same value as that measured using the inventive procedure. Consequently, the procedure tracks that measured by the blood very quickly.

25

This invention has been described and specific examples of the invention have been portrayed. The use of those specifics is not intended to limit the invention in any way. Additionally, to the extent there are variations of the invention with are within the spirit of the disclosure and yet are equivalent to the inventions found in the claims, it is our intent that this patent will cover those variations as well.

30

WE CLAIM AS OUR INVENTION:

1. An analyte level measurement device comprising:
 - a.) an infrared source for emitting an IR beam into an ATR plate, said IR beam having components at least in the region of a referencing wavelength and a measuring wavelength,
 - b.) said ATR plate having a measurement surface for contact with said human skin surface and for directing said IR beam against said human skin surface, and
 - c.) at least two IR sensors for simultaneously measuring absorbance of at least said referencing wavelength and said measuring wavelength.
2. The analyte measurement device of claim 1 wherein said ATR plate is configured to permit multiple internal reflections against said measurement surface prior to measuring said absorbance.
15
3. The analyte measurement device of claim 2 wherein said ATR plate is configured for 3-15 internal reflections against said measurement surface.
4. The analyte measurement device of claim 1 further comprising a pressure maintenance member for maintaining adequate pressure of said human skin surface against said ATR plate surface.
20
5. The analyte measurement device of claim 4 wherein said pressure maintenance member is configured to maintain a constant and above a selected minimum pressure of said human skin surface against said ATR plate surface.
25
6. The analyte measurement device of claim 1 further comprising a pressure measurement member situated to measure the pressure of said human skin surface against said ATR plate surface.
30

7. The analyte measurement device of claim 1 wherein said analyte is glucose and said referencing wavelength is between about 8.25 micrometers and about 8.75 micrometers.

5 8. The analyte measurement device of claim 1 wherein said analyte is glucose and said measuring wavelength is between about 9.50 micrometers and about 10.00 micrometers.

10 9. The analyte measurement device of claim 1 further comprising a beam splitter situated between said ATR plate and said at least two IR sensors to form two beams, said two beams for introduction each to one of said at least two IR sensors.

10. The analyte measurement device of claim 1 wherein
15 a.) a first of said at least two IR sensors measures said measuring wavelength and provides a measuring signal related to absorbance of said measuring wavelength, and
b.) a second of said at least two IR sensors measures said referencing wavelength and provides a referencing signal related to absorbance of said referencing wavelength.

20 11. The analyte measurement device of claim 9 wherein
a.) a first of said at least two IR sensors measures said measuring wavelength and provides a measuring signal related to absorbance of said measuring wavelength; and
25 b.) a second of said at least two IR sensors measures said referencing wavelength and provides a referencing signal related to absorbance of said referencing wavelength.

30 12. The analyte measurement device of claim 10 wherein said analyte is glucose and further comprising a comparator for comparing said measuring signal to said referencing signal and providing a signal indicative of blood glucose concentration.

13. The analyte measurement device of claim 10 wherein said analyte is glucose and further comprising a computer component for comparing said measuring signal to said referencing signal and providing a digital signal indicative of blood glucose concentration.

5 14. The analyte measurement device of claim 12 further comprising a display for displaying said blood glucose concentration.

15. The analyte measurement device of claim 13 further comprising a display for displaying said blood glucose concentration.

10

16. The analyte measurement device of claim 1 wherein said infrared source is a broadband source.

15

17. The analyte measurement device of claim 1 wherein said infrared source is a non-laser source.

18. The analyte measurement device of claim 1 wherein said infrared source comprises two selected wavelength lasers.

20

19. A method for determining the blood glucose level in a human being using a glucose measurement device, comprising the steps of.

a.) contacting a skin surface on said human being with an ATR plate in said glucose measurement device, said ATR plate having a surface for contact with said human skin surface,

25 b.) irradiating said human skin surface with an IR beam having components at least in the region of a referencing wavelength and a measuring wavelength through said ATR plate to produce a reflected IR beam indicative of the blood glucose level in said human being, and

30 c.) detecting and quantifying said referencing wavelength and said measuring wavelength components in said reflected IR beam.

20. The method of claim 19 further comprising the step of maintaining said skin surface on said ATR plate at an adequate pressure.

5 21. The method of claim 19 further comprising the step of maintaining said skin surface on said ATR plate at a constant and above a selected minimum pressure.

22. The method of claim 19 further comprising the step of measuring the pressure of said skin surface on said ATR plate and maintaining said pressure at a relatively constant and above a selected minimum pressure.

10

23. The method of claim 19 further comprising the step of normalizing the glucose measurement device by simultaneously detecting and quantifying said referencing wavelength and said measuring wavelength components in said reflected IR beam prior to the step of contacting said skin surface on said human being to said ATR plate.

15

24. The method of claim 19 wherein said referencing wavelength is between about 8.25 micrometers and about 8.75 micrometers.

20

25. The method of claim 19 wherein said measuring wavelength is between about 9.50 micrometers and about 10.00 micrometers.

26. The method of claim 19 further comprising splitting said reflected beam to form two beams and introducing said two beams each to one of at least two IR sensors.

25

27. The method of claim 19 further comprising the steps of
a.) measuring the absorbance of said measuring wavelength in a first of said at least two IR sensors and providing a measuring signal related to the absorbance of said measuring wavelength and

30

b.) measuring the absorbance of said referencing wavelength in a second of said at least two IR sensors and providing a referencing signal related to the absorbance of said referencing wavelength.

28. The method of claim 27 further comprising the steps of comparing said measuring signal to said referencing signal and providing a signal indicative of blood glucose concentration.

5 29. The method of claim 27 further comprising the steps of comparing said measuring signal to said referencing signal with a digital computer and providing a digital signal indicative of blood glucose concentration.

10 30. The method of claim 28 further comprising the step of calculating said blood glucose concentration using stored calibration constants.

31. The method of claim 29 further comprising the step of calculating said blood glucose concentration using stored calibration constants.

15 32. The method of claim 30 further comprising the step of displaying said glucose concentration.

33. The method of claim 31 further comprising the step of displaying said glucose concentration.

20 34. The method of claim 19 wherein said irradiating step comprises the step of actuating broadband infrared source.

25 35. The method of claim 19 wherein said irradiating step comprises the step of actuating a non-laser infrared source.

36. The method of claim 19 wherein said irradiating step comprises the step of actuating two selected wavelength lasers.

30 37. A method for determining the analyte level in a human being using an analyte measurement device, comprising the steps of.

a.) contacting a skin surface on said human being with an ATR plate in said analyte measurement device, said ATR plate having a surface for contact with said human skin surface,

5 b.) irradiating said human skin surface with an IR beam having components at least in the region of a referencing wavelength and a measuring wavelength through said ATR plate to produce a reflected IR beam indicative of the analyte level in said human being, and

c.) detecting and quantifying said referencing wavelength and said measuring wavelength components in said reflected IR beam.

10

38. The method of claim 37 further comprising splitting said reflected beam to form two beams and introducing said two beams each to one of at least two IR sensors.

15

39. The method of claim 38 further comprising the steps of

a.) measuring the absorbance of said measuring wavelength in a first of said at least two IR sensors and providing a measuring signal related to the absorbance of said measuring wavelength and

20 b.) measuring the absorbance of said referencing wavelength in a second of said at least two IR sensors and providing a referencing signal related to the absorbance of said referencing wavelength.

40. The method of claim 37 further comprising the steps of comparing said measuring signal to said referencing signal and providing a signal indicative of said analyte level.

25

41. The method of claim 39 further comprising the steps of comparing said measuring signal to said referencing signal with a digital computer and providing a digital signal indicative of said analyte level.

30

42. The method of claim 40 further comprising the step of calculating said analyte level using stored calibration constants.

43. The method of claim 41 further comprising the step of calculating said analyte level using stored calibration constants.

5 44. The method of claim 42 further comprising the step of displaying said analyte level.

45. The method of claim 43 further comprising the step of displaying said analyte level.

10 46. The method of claim 37 wherein said irradiating step comprises the step of actuating broadband infrared source.

47. The method of claim 37 wherein said irradiating step comprises the step of actuating a non-laser infrared source.

15 48. The method of claim 37 wherein said irradiating step comprises the step of actuating two selected wavelength lasers.

20 49. A cleaning kit comprising :
a.) a glucose solvent, and
b.) a solvent for removing the glucose solvent, and
c.) a skin softener or skin pliability enhancer not having significant IR wavelength peaks between about 8.25 micrometers and about 8.75 micrometers or between about 9.50 micrometers and about 10.00 micrometers.

25 50. The cleaning kit of claim 49 wherein said solvent for removing the glucose solvent and skin softener or pliability enhancer are admixed.

30 51. The cleaning kit of claim 50 wherein each of said glucose solvent, and said admixed solvent for removing the glucose solvent and skin softener or pliability enhancer are present in sealed packets.

52. The cleaning kit of claim 49 wherein each of said glucose solvent, solvent for removing the glucose solvent, and skin softener or pliability enhancer are present in sealed packets.

5 53. The cleaning kit of claim 49 wherein said solvent for removing the glucose solvent has no significant IR wavelength peaks between about 8.25 micrometers and about 8.75 micrometers or between about 9.50 micrometers and about 10.00 micrometers.

10 54. The cleaning kit of claim 49 wherein each of said glucose solvent, solvent for removing the glucose solvent, and skin softener or pliability enhancer are present in an absorbent pad within said sealed packets.

15 55. The cleaning kit of claim 50 wherein each of said glucose solvent and said admixed solvent for removing the glucose solvent and skin softener or pliability enhancer are present in an absorbent pad within sealed packets.

56. The cleaning kit of claim 49 wherein the glucose solvent comprises water or other highly polar solvent.

20 57. The cleaning kit of claim 56 wherein the glucose solvent further comprises an effective amount of a weak acid having no significant IR wavelength peaks between about 8.25 micrometers and about 8.75 micrometers or between about 9.50 micrometers and about 10.00 micrometers.

25 58. The cleaning kit of claim 57 wherein the weak acid comprises boric acid.

59. The cleaning kit of claim 49 wherein the solvent for removing the glucose solvent comprises isopropanol.

30 60. The cleaning kit of claim 49 wherein the skin softener or pliability enhancer comprises a mineral oil.

61. A method for determining the blood glucose level in a human being using a glucose measurement device, comprising the steps of:

5 a.) irradiating human skin with light containing at least a mid-IR component so to produce a reflected mid-IR beam indicative of the blood glucose level in said human being, and

 b.) detecting and analyzing said reflected mid-IR beam to determine said blood glucose level.

10 62. The method of claim 61 wherein said human skin has a stratum corneum and said mid-IR component does not penetrate below said stratum corneum.

15 63. The method of claim 61 wherein said human skin has a basal layer and said mid-IR component penetrates into said human skin only above said basal layer.

20 64. The method of claim 61 wherein said light containing at least a mid-IR component is of a strength such that it does not penetrate human skin to a depth sufficient to reach vascular structure.

25 65. The method of claim 61 wherein said reflected mid-IR beam has not penetrated said human skin to a depth sufficient to reach vascular structure.

66. The method of claim 61 wherein said reflected mid-IR beam contains at least a component wavelength between about 8.25 micrometers and about 8.75 micrometers.

25 67. The method of claim 61 wherein said reflected mid-IR beam contains at least a component wavelength between about 9.50 micrometers and about 10. 00 micrometers.

68. A method for determining the blood glucose level in a human being using a glucose measurement device, comprising the steps of:

30 a.) irradiating a human body region substantially free of cholesterol, water, gamma globulin, albumin, and blood with light containing at least a mid-IR component so

to produce a reflected mid-IR beam indicative of the blood glucose level in said human being, and

5 b.) detecting and analyzing said reflected mid-IR beam to determine said blood glucose level.

5

69. The method of claim 68 wherein said reflected mid-IR beam contains at least a component wavelength between about 8.25 micrometers and about 8.75 micrometers.

10

70. The method of claim 68 wherein said reflected mid-IR beam contains at least a component wavelength between about 9.50 micrometers and about 10.00 micrometers.

71. A method for the analysis of a mid-IR beam containing at least a selected measuring wavelength having a level indicative of an analyte level in a human being comprising the steps of:

15

a.) quantifying said referencing wavelength in said mid-IR beam to produce a quantified measuring wavelength,
b.) comparing said quantified measuring wavelength to a reference, and
c.) calculating said analyte level by ratio of said quantified measuring wavelength to said reference.





20


72. The method of claim 71 wherein said mid-IR beam containing at least a selected measuring wavelength comprises a reflected mid-IR beam.

25

73. The method of claim 71 wherein said selected measuring wavelength is indicative of blood glucose level.


74. The method of claim 71 wherein said selected measuring wavelength is indicative of blood glucose level.





FOR GLUCOSE, WAVELENGTH (MICROMETERS)

FIG. 2







FIG. 4






FIG. 6





FIG. 8






FIG. 9